Antipsychotic-induced weight gain is a major management problem for clinicians. It has
been shown that weight gain and obesity lead to increased cardiovascular and …

Objective Leptin may play a role in the pathophysiology of schizophrenia and it remains
unclear if levels are raised compared to controls. Therefore, we performed a systematic …

Objectives: Weight gain is a major side effect of antipsychotics (APs), which contributes to
poor treatment adherence and significant morbidity. The mechanisms involved in AP …

Second-generation antipsychotics (SGAs) are known to increase cardiovascular risk through
several physiological mechanisms, including insulin resistance, hepatic steatosis …

Second generation antipsychotic drugs (SGAs) cause substantial body weight gain/obesity
and other metabolic side-effects such as dyslipidaemia. Their antagonistic affinity to the …

Abstract Objective Antipsychotics (APs) are associated with metabolic syndrome, with
increases in leptin proposed as an underlying mechanism of AP‐induced weight gain …

The metabolic syndrome (MetS) comprises abdominal obesity, preclinical or full diabetes
type 2, arterial hypertension, and dyslipidemia and affects a significant proportion of the …

Although the use of atypical antipsychotic drugs has been successful in the treatment of
schizophrenia, they can cause some complications in the long-term use, including weight …

Meal-induced insulin sensitization (MIS), an endogenous adaptive mechanism is activated
post-prandially. Reduced MIS leads to diabetes, but its activation improves insulin …

The use of antipsychotic drugs has started a new era in the treatment of psychotic disorders.
Nevertheless, they cause complications in the long-term treatment, which is mainly weight …